These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 38833993)
1. Comprehensive next-generation sequencing identifies novel putative pathogenic or likely pathogenic germline variants in patients with concurrent tubo-ovarian and endometrial serous and endometrioid carcinomas or precursors. Aisagbonhi O; Ghlichloo I; Hong DS; Roma A; Fadare O; Eskander R; Saenz C; Fisch KM; Song W Gynecol Oncol; 2024 Aug; 187():241-248. PubMed ID: 38833993 [TBL] [Abstract][Full Text] [Related]
2. Does serous tubal intraepithelial carcinoma (STIC) metastasize? The clonal relationship between STIC and subsequent high-grade serous carcinoma in BRCA1/2 mutation carriers several years after risk-reducing salpingo-oophorectomy. van den Berg CB; Dasgupta S; Ewing-Graham PC; Bart J; Bulten J; Gaarenstroom KN; de Hullu JA; Mom CH; Mourits MJE; Steenbeek MP; van Marion R; van Beekhuizen HJ Gynecol Oncol; 2024 Aug; 187():113-119. PubMed ID: 38759517 [TBL] [Abstract][Full Text] [Related]
4. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma]. Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967 [No Abstract] [Full Text] [Related]
5. Incidence of germline BRCA1/2 mutations in women with tubo-ovarian high-grade serous carcinomas with and without serous tubal intra-epithelial carcinomas. Dowson CB; Stewart C; O'Sullivan S; Pachter N; Schofield L; Cohen PA Int J Gynecol Cancer; 2020 Jan; 30(1):94-99. PubMed ID: 31699802 [TBL] [Abstract][Full Text] [Related]
6. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study. Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714 [TBL] [Abstract][Full Text] [Related]
7. The genomic trajectory of ovarian high-grade serous carcinoma can be observed in STIC lesions. Cheng Z; Ennis DP; Lu B; Mirza HB; Sokota C; Kaur B; Singh N; Le Saux O; Russo G; Giannone G; Tookman LA; Krell J; Barnes C; McDermott J; McNeish IA J Pathol; 2024 Sep; 264(1):42-54. PubMed ID: 38956451 [TBL] [Abstract][Full Text] [Related]
8. Murine Oviductal High-Grade Serous Carcinomas Mirror the Genomic Alterations, Gene Expression Profiles, and Immune Microenvironment of Their Human Counterparts. McCool KW; Freeman ZT; Zhai Y; Wu R; Hu K; Liu CJ; Tomlins SA; Fearon ER; Magnuson B; Kuick R; Cho KR Cancer Res; 2020 Feb; 80(4):877-889. PubMed ID: 31806642 [TBL] [Abstract][Full Text] [Related]
9. Mixed endometrial carcinomas with a "low-grade serous"-like component: a clinicopathologic, immunohistochemical, and molecular genetic study. Espinosa I; D'Angelo E; Corominas M; Gonzalez A; Prat J Hum Pathol; 2018 Jan; 71():65-73. PubMed ID: 29079180 [TBL] [Abstract][Full Text] [Related]
10. Long-term outcome of high-grade serous carcinoma established in risk-reducing salpingo-oophorectomy specimens in asymptomatic BRCA1/2 germline pathogenic variant carriers. Stroot IAS; Bart J; Hollema H; Jalving M; Wagner MM; Yigit R; van Doorn HC; de Hullu JA; Gaarenstroom KN; van Beurden M; van Lonkhuijzen LRCW; Slangen BFM; Zweemer RP; Gómez García EB; Ausems MGEM; Boere IA; van Hest LP; Duijkers FAM; van Asperen CJ; Schmidt MK; Wevers MR; Ruijs MWG; Devilee P; Collée JM; Hebon Investigators ; de Bock GH; Mourits MJE Gynecol Oncol; 2024 Aug; 187():198-203. PubMed ID: 38795508 [TBL] [Abstract][Full Text] [Related]
11. Endometrium is not the primary site of origin of pelvic high-grade serous carcinoma in BRCA1 or BRCA2 mutation carriers. Reitsma W; Mourits MJ; de Bock GH; Hollema H Mod Pathol; 2013 Apr; 26(4):572-8. PubMed ID: 23080033 [TBL] [Abstract][Full Text] [Related]
12. [Morphologic features of fallopian tubal epithelium in pelvic high-grade serous carcinoma]. Zhao RJ; Wang YY; Li Z; Wu KY; Kong LF; Zheng WX Zhonghua Bing Li Xue Za Zhi; 2017 Aug; 46(8):542-547. PubMed ID: 28810294 [No Abstract] [Full Text] [Related]
13. [Oncopathological aspects of BRCA1 and BRCA2 genes inactivation in tumors of ovary, fallopian tube and pelvic peritoneum]. Škapa P; Dundr P Cesk Patol; 2016; 52(4):199-204. PubMed ID: 27869446 [TBL] [Abstract][Full Text] [Related]
14. The prevalence of occult ovarian cancer in the series of 155 consequently operated high risk asymptomatic patients - Slovenian population based study. Gornjec A; Merlo S; Novakovic S; Stegel V; Gazic B; Perhavec A; Blatnik A; Krajc M Radiol Oncol; 2020 May; 54(2):180-186. PubMed ID: 32463390 [TBL] [Abstract][Full Text] [Related]
16. Incidental nonuterine high-grade serous carcinomas arise in the fallopian tube in most cases: further evidence for the tubal origin of high-grade serous carcinomas. Gilks CB; Irving J; Köbel M; Lee C; Singh N; Wilkinson N; McCluggage WG Am J Surg Pathol; 2015 Mar; 39(3):357-64. PubMed ID: 25517954 [TBL] [Abstract][Full Text] [Related]
17. Outcomes of Incidental Fallopian Tube High-Grade Serous Carcinoma and Serous Tubal Intraepithelial Carcinoma in Women at Low Risk of Hereditary Breast and Ovarian Cancer. Chay WY; McCluggage WG; Lee CH; Köbel M; Irving J; Millar J; Gilks CB; Tinker AV Int J Gynecol Cancer; 2016 Mar; 26(3):431-6. PubMed ID: 26807643 [TBL] [Abstract][Full Text] [Related]
19. Targeted Sequencing of Tubo-ovarian and Peritoneal High-grade Serous Carcinoma With Wild-type p53 Immunostaining Pattern. Kim HN; Woo HY; DO SI; Kim HS In Vivo; 2019; 33(5):1485-1492. PubMed ID: 31471396 [TBL] [Abstract][Full Text] [Related]
20. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer. Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]